Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Nuvectis Pharma (NVCT) Assets Average (2022 - 2026)

Nuvectis Pharma has reported Assets Average over the past 5 years, most recently at $28.6 million for Q1 2026.

  • Quarterly results put Assets Average at $28.6 million for Q1 2026, up 17.13% from a year ago — trailing twelve months through Mar 2026 was $28.6 million (up 17.13% YoY), and the annual figure for FY2025 was $25.2 million, up 33.14%.
  • Assets Average reached $28.6 million in Q1 2026 per NVCT's latest filing, down from $33.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $33.6 million in Q4 2025 and bottomed at $12.1 million in Q1 2022.
  • Median Assets Average over the past 5 years was $20.6 million (2023), compared with a mean of $22.0 million.
  • The largest annual shift saw Assets Average dropped 24.57% in 2024 before it skyrocketed 87.38% in 2025.
  • Over 5 years, Assets Average stood at $22.6 million in 2022, then fell by 8.45% to $20.7 million in 2023, then fell by 13.35% to $18.0 million in 2024, then surged by 87.38% to $33.6 million in 2025, then decreased by 15.14% to $28.6 million in 2026.
  • Business Quant data shows Assets Average for NVCT at $28.6 million in Q1 2026, $33.6 million in Q4 2025, and $31.3 million in Q3 2025.